These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16153830)

  • 1. Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
    Dowling JE; Vessels JT; Haque S; Chang HX; van Vloten K; Kumaravel G; Engber T; Jin X; Phadke D; Wang J; Ayyub E; Petter RC
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4809-13. PubMed ID: 16153830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
    Yao G; Haque S; Sha L; Kumaravel G; Wang J; Engber TM; Whalley ET; Conlon PR; Chang H; Kiesman WF; Petter RC
    Bioorg Med Chem Lett; 2005 Feb; 15(3):511-5. PubMed ID: 15664803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
    Neustadt BR; Hao J; Lindo N; Greenlee WJ; Stamford AW; Tulshian D; Ongini E; Hunter J; Monopoli A; Bertorelli R; Foster C; Arik L; Lachowicz J; Ng K; Feng KI
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1376-80. PubMed ID: 17236762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Chen L; Zhang J; Petter RC
    J Med Chem; 2004 Aug; 47(17):4291-9. PubMed ID: 15294001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
    Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
    J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.
    Vu CB; Pan D; Peng B; Sha L; Kumaravel G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Petter RC
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4831-4. PubMed ID: 15341933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships.
    Azam F; Ibn-Rajab IA; Alruiad AA
    Pharmazie; 2009 Dec; 64(12):771-95. PubMed ID: 20095134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.
    Shah U; Lankin CM; Boyle CD; Chackalamannil S; Greenlee WJ; Neustadt BR; Cohen-Williams ME; Higgins GA; Ng K; Varty GB; Zhang H; Lachowicz JE
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4204-9. PubMed ID: 18558486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
    Shah U; Boyle CD; Chackalamannil S; Neustadt BR; Lindo N; Greenlee WJ; Foster C; Arik L; Zhai Y; Ng K; Wang S; Monopoli A; Lachowicz JE
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4199-203. PubMed ID: 18562199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Pan D; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Petter RC
    J Med Chem; 2005 Mar; 48(6):2009-18. PubMed ID: 15771443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease.
    Volpini R; Dal Ben D; Lambertucci C; Marucci G; Mishra RC; Ramadori AT; Klotz KN; Trincavelli ML; Martini C; Cristalli G
    ChemMedChem; 2009 Jun; 4(6):1010-9. PubMed ID: 19343763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.
    Harris JM; Neustadt BR; Zhang H; Lachowicz J; Cohen-Williams M; Varty G; Hao J; Stamford AW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2497-501. PubMed ID: 21398125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
    J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
    Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Higgins GA; Cohen-Williams ME; Varty GB; Tulshian DB
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3675-8. PubMed ID: 15982882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
    Vu CB; Shields P; Peng B; Kumaravel G; Jin X; Phadke D; Wang J; Engber T; Ayyub E; Petter RC
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4835-8. PubMed ID: 15341934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.
    Gillespie RJ; Bamford SJ; Clay A; Gaur S; Haymes T; Jackson PS; Jordan AM; Klenke B; Leonardi S; Liu J; Mansell HL; Ng S; Saadi M; Simmonite H; Stratton GC; Todd RS; Williamson DS; Yule IA
    Bioorg Med Chem; 2009 Sep; 17(18):6590-605. PubMed ID: 19695884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
    Matasi JJ; Caldwell JP; Zhang H; Fawzi A; Cohen-Williams ME; Varty GB; Tulshian DB
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3670-4. PubMed ID: 15978806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.
    Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS
    Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
    Gillespie RJ; Adams DR; Bebbington D; Benwell K; Cliffe IA; Dawson CE; Dourish CT; Fletcher A; Gaur S; Giles PR; Jordan AM; Knight AR; Knutsen LJ; Lawrence A; Lerpiniere J; Misra A; Porter RH; Pratt RM; Shepherd R; Upton R; Ward SE; Weiss SM; Williamson DS
    Bioorg Med Chem Lett; 2008 May; 18(9):2916-9. PubMed ID: 18406614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.